Job Description
We seek highly motivated Postdoctoral Fellows interested in developing independent research projects in the area of cell signaling at the interface of development, stem cells and cancer. Candidates will join the group of Dr. Andres Lebensohn, an Earl Stadtman Principal Investigator in the Laboratory of Cellular and Molecular Biology (LCMB) at the Center for Cancer Research (CCR) of the National Cancer Institute (NCI). We combine functional genomics, CRISPR/Cas9-mediated genome editing, cell biology and biochemistry to study how signaling pathways are used, reused and repurposed to drive the myriad different cellular processes that give rise to tissues and organs during embryonic development and maintain them in adult life. A major focus of the lab is on WNT signaling, a fundamental pathway that orchestrates embryonic patterning and morphogenesis, and promotes stem cell self-renewal and tissue regeneration. We use powerful genetic screens in human cells to discover new regulatory mechanisms. We probe their molecular underpinning through genetics, biochemistry and cell biology. We seek to unravel their physiological and pathological functions using organoid cultures and animal models. Based on this understanding, we strive to devise more selective therapeutic strategies to target tumors driven by dysregulation of WNT signaling. Descriptions of specific research projects can be found on the Lebensohn Lab website. Fellows will have exceptional stipend support for the entire duration of their post-doc, full healthcare benefits and funds for travel to scientific conferences.
Qualifications and Job Details
Required and Preferred Skills
Candidates must have completed a Ph.D. within the past 3 years. At least one first/co-first authored manuscript (published or submitted) is highly recommended.
Candidates with backgrounds in cell, stem cell, developmental or cancer biology are encouraged to apply. Experience in biochemistry, cell biology, organoid tissue culture or mouse genetics is welcome but not required.
About the NCI Center for Cancer Research
The Center for Cancer Research (CCR) is home to nearly 250 basic and clinical research groups located on two campuses just outside of Washington, D.C. CCR is part of the National Cancer Institute (NCI) and makes up the largest component of the research effort at the National Institutes of Health (NIH). Centrally supported by long-term funding and a culture of complete intellectual freedom, CCR scientists are able to pursue the most important and challenging problems in cancer research. We collaborate with academic and commercial partners and advocacy groups across the world in efforts to prevent, diagnose and treat cancer and HIV/AIDS. The CCR research portfolio covers the full spectrum of biological and biomedical research. Our work ranges from basic to translational and clinical, and our clinical trials are conducted in the NIH Clinical Center, the world’s largest hospital dedicated to clinical research that offers a robust infrastructure to support CCR’s patients on an estimated 250 open studies. The success of CCR is grounded in an exceptionally strong discovery research program that provides the foundation for the seamless translation of insights from bench to bedside. Read more about CCR, the benefits of working at CCR and hear from our staff on their CCR experiences.
Bethesda
Bethesda is one of the most highly educated communities in the United States and has a nationally renowned school system. The city is a thriving suburban center close to Washington, D.C., and home to many restaurants, retailers and a flourishing arts and entertainment district.
In your cover letter, describe: A) your previous research accomplishments, clearly stating the key findings and significance of your work; B) your future interests, explicitly stating why you are interested in our research and which projects inspire you.
Attach a CV including A) bibliography and B) contact information for three references.
Use the following email subject: “Application for postdoctoral fellow position in the Lebensohn Lab”